Alkermes plc (ALKS) — Fair Value Analysis

Base-case fair value (P50): $41.80 · Current price: $35.55 · Verdict: Undervalued

The Verdict on ALKS

Monte Carlo simulations suggest ALKERMES (ALKS) is currently Fairly Valued, despite trading below its estimated median fair value. With ALKS's current price at $35.55, our analysis places its median fair value (P50) at $41.80. This represents a potential upside of +17.6% from the current trading level, indicating that the market has not yet fully priced in the company's intrinsic value as projected across thousands of forward-looking scenarios. The "Fairly Valued" verdict takes into account this gap alongside the broader distribution of potential outcomes, suggesting that while upside exists, it falls within a reasonable range for a company of ALKS's profile within the Healthcare sector.

How ALKS stacks up against Healthcare

ALKERMES's operational and financial health is assessed as an "average" quality tier when benchmarked against its peers in the Healthcare sector. This evaluation factors into the Monte Carlo simulation, influencing the range and probability of future cash flows and, consequently, the resulting fair value distribution. The median fair value of $41.80 reflects the market's current assessment and future potential of a company with this average quality profile. While the $35.55 current price offers a +17.6% discount to this median, it aligns with a scenario where the market is cautiously optimistic, perhaps waiting for further catalysts given its average standing within a dynamic sector.

What this means for investors

For investors, ALKS's designation as Fairly Valued—with a median fair value of $41.80 against its current price of $35.55—suggests a balanced risk-reward profile, even with the +17.6% potential upside to the P50. While the simulations point to a higher intrinsic value, the "Fairly Valued" verdict cautions against overinterpretation of the median alone, acknowledging the full spectrum of potential outcomes generated by our Monte Carlo analysis. This nuanced perspective, including downside and upside scenarios, is critical. Sign up for FairCurve to see the full bear/bull distribution and track ALKS's fair value as new fundamentals are released.